$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Biogen posts a strong Q2 FY2025 beat and raises EPS guidance, but ongoing MS franchise declines and one-off revenue drivers temper the outlook.

# Biogen Delivers Strong Q2 FY2025 Beat with Upgraded Guidance, but MS Headwinds Persist

---

## Executive Summary

- **Biogen (BIIB) delivered a robust Q2 FY2025, beating both revenue and EPS expectations**. Revenue reached **$2.646B** (up 7% YoY), and non-GAAP EPS came in at **$5.47**—a substantial **$1.56 per share beat** versus consensus. The outperformance was driven by a one-off boost in contract manufacturing and a sharp increase in Alzheimer’s collaboration revenue, partially offset by continued declines in the MS franchise.
- **Earnings quality remains high**, with net margin at **9.89%** and strong returns on equity and assets. The company’s ongoing “Fit for Growth” cost discipline program is on track, supporting margin expansion and operational efficiency.
- **Management struck a bullish tone**, raising FY2025 non-GAAP EPS guidance to **$15.50–$16.00** (from $14.50–$15.50) and reiterating a flat revenue outlook. New product launches (LEQEMBI, ZURZUVAE) and proactive investments in manufacturing capacity underpin a cautiously optimistic outlook.
- **Risks remain**, particularly around regulatory developments, ongoing MS segment erosion, and the sustainability of recent contract manufacturing gains. However, **opportunities** include a $2B U.S. manufacturing expansion, a strengthening pipeline, and reduced short interest, all of which could drive future upside.
- **Catalyst watch:** Investors should monitor upcoming LEQEMBI long-term data, progress in Phase 3 trials for felzartamab, and further updates on the manufacturing expansion as key near-term drivers.

---

## Performance Snapshot

| Metric                | Reported | Consensus | Surprise | YoY Change |
|-----------------------|----------|-----------|----------|------------|
| Revenue               | $2.646B  | $2.48B    | +$166M   | +7%        |
| Non-GAAP EPS          | $5.47    | $3.91     | +$1.56   | +XX%*      |
| Alzheimer’s Collab Rev| $55M     | $12M      | +$43M    | +358%      |
| MS Product Revenue    | $1.13B   | —         | —        | -4%        |

*YoY EPS growth not specified in source.

---

## Earnings Quality

- **Revenue mix was favorably impacted by a one-time acceleration in contract manufacturing and a surge in Alzheimer’s collaboration revenue**, while the core MS franchise continued to decline.
- **Margins remain robust**: Net margin at 9.89% and strong returns on equity/assets reflect effective cost management. The “Fit for Growth” program is on track to deliver $1B gross and $800M net savings by end-2025, supporting ongoing margin expansion.
- **Profitability outpaced sales growth**, with cost controls and operational efficiency offsetting segmental headwinds.

---

## Management Commentary & Guidance

- **Management’s tone was bullish**, emphasizing strong execution, a transforming portfolio, and proactive investments in new product launches and manufacturing.
- **Guidance was raised**: FY2025 non-GAAP EPS now expected at $15.50–$16.00 (up from $14.50–$15.50), with revenue projected to be flat YoY. This reflects confidence in operational momentum and cost discipline, despite sector headwinds.
- **Assumptions** include continued cost savings, stable contract manufacturing contributions, and incremental revenue from new launches.

---

## Key Risks

- **Regulatory risk**: Ongoing FDA review dynamics and pipeline approval uncertainties, especially with a new CDER head.
- **MS franchise decline**: Continued competitive and pricing pressures, particularly ex-US.
- **Sustainability of contract manufacturing gains**: Recent revenue boost may not be repeatable in future quarters.

---

## Expected Market Reaction

- **Analyst sentiment is cautiously optimistic**: The significant EPS beat and raised guidance are positives, but persistent MS headwinds and the one-off nature of some revenue drivers may temper enthusiasm.
- **Market may be underpricing** Biogen’s cost discipline and pipeline potential, while overemphasizing MS franchise risks. A sustained operational turnaround could prompt a re-rating.

---

## Final Takeaway

- **Q2 FY2025 was a strong quarter for Biogen**, marked by a clear beat on key metrics, robust cost controls, and upgraded guidance. However, the sustainability of recent revenue drivers and ongoing MS headwinds warrant caution.
- **The market may be underappreciating** Biogen’s operational improvements and pipeline optionality, while over-discounting the MS decline.
- **Upcoming catalysts**: LEQEMBI long-term data, Phase 3 felzartamab trial updates, and progress on the $2B North Carolina manufacturing expansion will be critical for sentiment and valuation.

---

Biogen Q2 Beat: Guidance Raised, MS Risks Remain

Biogen’s accelerating rare disease growth and US manufacturing expansion are offsetting MS portfolio declines, but margin compression and regulatory risks temper near-term optimism.

# Biogen Inc.: Rare Disease Momentum and Manufacturing Resilience Set the Stage for Next Quarter’s Earnings

## Executive Summary: Cautious Optimism as Rare Disease Outperformance Offsets MS Headwinds

We hold a **Neutral-to-Bullish** outlook for Biogen Inc. (NASDAQ: BIIB) heading into the upcoming quarter. While **Q1 2025 revenue of $2.43B (+6.1% YoY)** and **EPS of $3.02** both exceeded consensus, margin compression (operating margin down to **12.8%** from 20.3% YoY) tempers enthusiasm. The market may be underestimating the **accelerating rare disease franchise** (over **30% YoY growth**) and the operational buffer provided by Biogen’s US manufacturing expansion, which together could offset ongoing MS portfolio erosion. However, persistent generic competition and regulatory pricing risks remain key overhangs.

**Key overlooked insight:** Management’s tone and capex commitments suggest a deeper operational confidence and earlier-than-expected yield improvements, not fully reflected in consensus models.

## Recent Trends Signal What’s Next: Revenue Growth Moderates, Margins Under Pressure

Biogen’s last two quarters highlight a **pivot in revenue mix** and a **downward trend in margins**. Q1 2025 revenue grew 6.1% YoY to $2.43B, but **gross margin slipped to 74%** (from 76% in Q4 2024) and **operating margin fell to 12.8%** (from 20.3% YoY). The rare disease segment surged over 30% YoY, while MS revenue declined 11% YoY, signaling a shift in growth drivers.

### Quarterly Financial Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS   |
|--------------|--------------|------------------|----------------------|-------|
| Q2 2024      | 2.28         | 77.2             | 19.8                 | 2.85  |
| Q3 2024      | 2.31         | 76.5             | 18.5                 | 2.92  |
| Q4 2024      | 2.37         | 76.0             | 20.3                 | 3.01  |
| Q1 2025      | 2.43         | 74.0             | 12.8                 | 3.02  |

**Trend:** Revenue is rising modestly, but both gross and operating margins are compressing, reflecting higher costs and MS franchise pressure.

## Management’s Forward Tone and Positioning: Cautious on MS, Confident on Rare Disease and Operations

Management’s Q1 2025 commentary struck a **measured but optimistic tone**. CEO Christopher Viehbacher described the quarter as a “very good start,” but flagged MS headwinds:  
> “We’re seeing early signs of normalization in demand for our rare disease portfolio, while MS remains under pressure.” (Q1 2025 Earnings Call)

The shift from last quarter’s “cautiously optimistic” language to “encouraged by the performance of new launches” signals growing confidence in rare disease and pipeline execution. The **revised full-year EPS guidance of $14.50–$15.50** (down from $15.00–$16.00) reflects prudent caution, primarily due to a one-time expense, not a fundamental demand issue.

Notably, management downplayed tariff risks:  
> “Tariff risks are not expected to significantly affect our outlook given our US manufacturing footprint.” (Q1 2025 10-Q)

This marks a subtle but important shift toward emphasizing operational resilience.

## KPI Trends & Upcoming Quarter Drivers: Rare Disease Growth, US Manufacturing, and Inventory Stability

**Key KPIs for Next Quarter:**
- **Rare Disease Revenue Growth:** +33% YoY in Q1 2025, driven by Spinraza and Skyclarys.
- **MS Franchise Revenue:** -11% YoY, with continued generic/biosimilar erosion.
- **US Manufacturing Output:** >90% of medicines produced domestically; $2B capex expansion underway.

### KPI Movement Table

| KPI                        | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|----------------------------|---------|---------|---------|------------|------------|
| Rare Disease Revenue ($M)  | 410     | 520     | 545     | +33%       | +4.8%      |
| MS Revenue ($M)            | 1,320   | 1,210   | 1,175   | -11%       | -2.9%      |
| US Manufacturing Output (%)| 88      | 90      | 92      | +4pp       | +2pp       |

**Implications:**  
- **Rare disease outperformance** is likely to drive top-line upside and partially offset MS declines.
- **US manufacturing and inventory stability** should help protect margins from supply chain and tariff shocks.
- **MS erosion** remains the primary risk to both revenue and margin.

## Missed by the Street: Operational Execution and Capex-Driven Upside

**Street Overlooked Signals:**
- **Capex Expansion:** Management’s reference to “continuing our multi-year capex expansion” (Q1 2025 10-Q) and robust inventory levels suggest earlier-than-expected operational leverage, not yet reflected in consensus.
- **Inventory Positioning:** The company’s “healthy global inventory levels” (Q1 2025 Earnings Call) point to supply chain resilience, which could support margin stabilization even if top-line growth moderates.

## Scenarios for the Upcoming Quarter: Bull, Base, and Bear Cases

### Scenario Table

| Scenario | Revenue ($B) | EPS   | Operating Margin (%) | Key Assumptions                                              |
|----------|--------------|-------|----------------------|--------------------------------------------------------------|
| Bull     | 2.45         | 3.10  | 13.0                 | Rare disease growth >35% YoY, minimal MS drag, cost control  |
| Base     | 2.43         | 3.00  | 12.8                 | Rare disease +30% YoY, MS -10% YoY, stable inventory         |
| Bear     | 2.40         | 2.90  | 12.0                 | Rare disease <25% YoY, MS -15% YoY, regulatory/pricing headwinds |

**Most Likely:** The **Base case** is most probable, given current rare disease momentum, stable US operations, and management’s measured guidance. Upside exists if rare disease launches accelerate further, but MS erosion and regulatory risks cap near-term optimism.

## Appendix – Data Tables & Management Quotes

### Quarterly Financials Table

| Quarter      | Revenue ($B) | EPS   | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|-------|------------------|----------------------|
| Q2 2024      | 2.28         | 2.85  | 77.2             | 19.8                 |
| Q3 2024      | 2.31         | 2.92  | 76.5             | 18.5                 |
| Q4 2024      | 2.37         | 3.01  | 76.0             | 20.3                 |
| Q1 2025      | 2.43         | 3.02  | 74.0             | 12.8                 |

### KPI Movement Table

| KPI                        | Q1 2024 | Q4 2024 | Q1 2025 | YoY Change | QoQ Change |
|----------------------------|---------|---------|---------|------------|------------|
| Rare Disease Revenue ($M)  | 410     | 520     | 545     | +33%       | +4.8%      |
| MS Revenue ($M)            | 1,320   | 1,210   | 1,175   | -11%       | -2.9%      |
| US Manufacturing Output (%)| 88      | 90      | 92      | +4pp       | +2pp       |

### Key Management Quotes

1. **“We’re seeing early signs of normalization in demand for our rare disease portfolio, while MS remains under pressure.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Rare disease is stabilizing as a growth engine, but MS headwinds persist.*

2. **“Tariff risks are not expected to significantly affect our outlook given our US manufacturing footprint.”**  
   *Source: Q1 2025 10-Q*  
   *Interpretation: Domestic production shields margins from external shocks.*

3. **“Continuing our multi-year capex expansion to support pipeline and manufacturing scale.”**  
   *Source: Q1 2025 10-Q*  
   *Interpretation: Capex investments may yield operational leverage sooner than expected.*

4. **“We are encouraged by the performance of new launches, particularly in rare diseases.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Management confidence in pipeline execution is rising.*

5. **“Adjusted EPS guidance reflects a one-time expense, not a change in underlying demand.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Guidance cut is not due to core business weakness.*

6. **“Healthy global inventory levels position us well for the next quarter.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: Supply chain risks are well managed.*

7. **“We expect continued pressure in the MS franchise due to generic competition.”**  
   *Source: Q1 2025 Earnings Call*  
   *Interpretation: MS remains a structural drag on growth and margins.*

---

**Bottom Line:**  
Biogen’s rare disease momentum and operational investments provide a credible buffer against MS erosion and regulatory risks. The next quarter’s results will hinge on the pace of rare disease adoption and the company’s ability to sustain margin stability amid ongoing headwinds. We see the **Base case** as most likely, with upside if rare disease launches outperform and operational leverage materializes ahead of schedule.

Biogen (BIIB): Rare Disease Growth Offsets MS Decline